Making sense of screening

July 03, 2015

Misconceptions about how screening works, its limitations and possible harms are still being perpetuated by media stories and high profile cases, such as Angelina Jolie's double mastectomy and emotive tabloid case studies of women under 25 dying from cervical cancer. Campaigners and celebrities still call for more screening: for more diseases, in more people and for longer. In the last few months alone, Taylor Swift encouraged fans' parents to get earlier breast screening following her mother's cancer diagnosis, campaigners have called for all women over 70 to be screened for breast cancer and researchers have been developing screening tests for Alzheimer's, as well as discussing screening babies from birth. There's also a widespread misconception that screening programmes are only offered to certain age groups due to financial considerations.

We have released a new edition of our guide Making Sense of Screening1 today to address the unrealistic expectations of what screening can deliver.

In the guide, scientists, clinicians and medics explain that screening: For more information and interviews please contact Sense About Science on +44 (0)20 7490 9590 or Out of hours, contact Emily Jesper on +44 (0)7863 140387.


Dr Anne Mackie, director of programmes for the UK National Screening Committee: "Screening is very different from asking your GP for a test. It is offered to a large number of people who are apparently healthy and not showing symptoms, which means that most people will be tested with no possibility of benefit.

"In addition, some people, rarely, will be given a result that suggests they have a problem when they don't, or even told they don't have a problem, when they do. That is why it is important that people make their own decision whether to attend for screening when offered - understanding there may be risks as well as benefits.

"We need to help people see that although screening is beneficial at the population level, they need to consider the implications for themselves as an individual. It is therefore so important that people, when invited, are given the full information before making a decision on whether to have a screening test."

Andrew Miller, former chair, House of Commons Science and Technology Select Committee: "This is an important piece of work against a background of confusion and misconceptions surrounding some screening programmes. I hope this public guide will be widely available as it could help to improve engagement between clinicians and the public."

Dr Danielle Freedman, chair, LabTestsOnLine, UK Board: "As professionals, we need to prevent overdiagnosis in healthy individuals causing 'pseudo disease' through 'unnecessary screening'. It leads to wasting of resources on unnecessary care, instead of using these precious resources for treating and preventing genuine illness."

Dr Suzy Lishman, president, The Royal College of Pathologists: "Screening plays an important role in keeping people healthy, but there are many misconceptions about its purpose and accuracy. The more people are aware of its benefits and limitations, the better equipped they will be to make decisions about whether to be tested and to understand the results they receive. Making Sense of Screening explains what screening aims to do, what the results mean and why there are screening programmes for some conditions but not others. I would recommend it to anyone to help them make informed decisions about their health care."

Sarah May, deputy chief executive, Institute of Biomedical Science: "A screening test in effect predicts risk; it does not give an absolute guarantee of disease absence or disease presence. A positive result means that further investigation is required. Some of those with positive results will be found to be at risk of developing a particular disease and others will be found to be clear. However, there will always be some false positives which should be offset by the benefit of detecting the low numbers of genuine 'at risk' individuals. A negative result means that no evidence of a particular disease or condition was found but it does not mean that the person will remain disease free in the future."

Emily Jesper, assistant director, Sense About Science: "Since Sense About Science first launched this guide in 2009, confusion, misconceptions and misinformation about screening have not gone away. The influence of celebrities and campaigners in the media and public discussion often amplifies this, which needs to stop. Continual calls for more screening ignores the risk of harm, which always need to be weighed against the benefits when making decisions about screening, both for national programmes and for individuals."

Joe O'Meara, government affairs officer, Association for Clinical Biochemistry and Laboratory Medicine: "I'm delighted to see the publication of the new edition of "Making Sense of Screening". There are many who do not understand, or have serious misconceptions about, screening. I hope that all involved in establishing screening programmes will take note so that our limited resources are deployed effectively and to the benefit of the whole population"

Dr Clare McKenzie, vice president for education, The Royal College of Obstetricians and Gynaecologists (RCOG): "People often get confused between screening and diagnostic tests. Screening is for women without symptoms. Cervical cancer screening can detect pre-cancer abnormalities, which can then be treated before it develops into cancer. As most women do not experience any symptoms at this stage, screening is the only way to find these abnormal cells.

"If women have any symptoms, such as abnormal bleeding, they should not wait for their next screening but instead be seen by their GP and referred for diagnostic tests and treatment if necessary. In the majority of cases a simple reason is found."

Sarah Williams health information manager, Cancer Research UK: "Cancer screening plays an important role in helping us beat cancer, through detecting the disease early and in some cases preventing it from starting in the first place, but as Sense About Science's useful report highlights the story isn't as straightforward as people often think. It's important that people have a sense of perspective about the benefits that screening can offer them - the most likely outcome from taking part in screening is that the test correctly finds you don't have cancer. And screening has potential harms too, so people should have clear and accurate information about both sides of the equation to help them decide whether they want to take part."

Robert Music, chief executive, Jo's Cervical Cancer Trust: "There has been much press coverage and petitions launched to lower the screening age following the diagnosis of cervical cancer in women under 25. It is tragic to see these young women going through a cancer diagnosis but expert opinion, which we like other charities have to be guided by, says that reducing the age at which a woman is first screened is unlikely to diagnose more cancers in those under 25 or prevent more deaths. There is also evidence that cervical screening is less effective in younger women and can cause more harm then good with unnecessary treatment.

Susan Bewley, professor of complex obstetrics, Kings College London: "Even in the old well-established screening programmes such as mammography, there is debate about the risks of screening and how often they occur. Women should be as well informed as possible about the potential risks, as well as the benefits, before starting on the screening journey. Fewer attend when they are fully and properly informed and understand it is not an unmitigated boon. I am saddened when I hear non-medical contemporaries discuss their distress about their own or their wife's "cancer" diagnosis when it was DCIS discovered on a mammogram. DCIS looks like cancer down a microscope but doesn't behave like cancer. It might never have developed into a problem. Women do not realise that the life-changing mastectomy, or even bilateral mastectomy, for DCIS was an adverse consequence of being screened. They should be told about the real risks and benefits to make their own, informed decisions."
Notes for editors

1. An embargoed copy of the new edition of, Making Sense of Screening can be downloaded at this private Dropbox link (not for publication):

After 0001 BST 3rd July 2015 an electronic version of the guide will be available to download from the Sense About Science website Sense About Science is a UK charity that puts science and evidence in the hands of public.

2. The new edition of the guide Making Sense of Screening is published by Sense About Science with the kind assistance of the Institute of Biomedical Science and The Royal College of Pathologists.

The Royal College of Pathologists ( is the professional organisation for pathologists, established by its Royal Charter to strive to improve the quality of pathology services for the public. The College is principally responsible for setting standards and professional examinations for pathologists.

The Institute of Biomedical Science ( is the professional body for biomedical scientists and is involved with the quality, promotion and practice of biomedical science. The Institute does this through a number of activities including: degree accreditation, the setting of professional standards, awarding professional qualifications and through its research grant programme. The Institute has a world-wide membership, advising national and international organisations on biomedical science and related matters.

3. Contributors to Making Sense of Screening: Michael Baum, Susan Bewley, Michael Fitzpatrick, Danielle Freedman, Peter Furness, Hedley Glencross, Síle Lane, Anne Mackie, Margaret McCartney, Joe O'Meara, Angela Raffle, Hazel Thornton, Ian Watson and Caroline Wright. Further details about the contributors can be found in the guide.


Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to